Advanced

Prophylactic treatment in Sweden - Overtreatment or optimal model?

Lee, C A; Kessler, C M; Varon, D; Martinowitz, U; Heim, M and Ljung, R.C.R. LU (1998) In Haemophilia 4(4). p.409-412
Abstract
At the haemophilia centre in Malmo, Sweden, regular prophylactic treatment is begun at 1-1 1/4 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the... (More)
At the haemophilia centre in Malmo, Sweden, regular prophylactic treatment is begun at 1-1 1/4 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the future. Were continuous infusion, using a recombinate concentrate with a prolonged half-life, technically feasible and socially acceptable to the child, we would probably have attained the optimal model of prophylactic treatment. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
keywords
Factor IX, Factor VIII, Haemophilia A, Haemophilia B, Prophylaxis, blood clotting factor, blood clotting factor 8, blood clotting factor 9, conference paper, continuous infusion, drug half life, hemarthrosis, hemophilia, human, metabolism, practice guideline, priority journal, prophylaxis, Sweden
in
Haemophilia
volume
4
issue
4
pages
409 - 412
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • Scopus:0031856486
ISSN
1351-8216
DOI
10.1046/j.1365-2516.1998.440409.x
language
English
LU publication?
yes
id
a4f0e61d-3b3e-4a15-9295-7a1eef995a94
date added to LUP
2016-11-25 14:54:13
date last changed
2016-11-29 10:23:17
@misc{a4f0e61d-3b3e-4a15-9295-7a1eef995a94,
  abstract     = {At the haemophilia centre in Malmo, Sweden, regular prophylactic treatment is begun at 1-1 1/4 years of age, before the onset of joint bleeds. The dose and dose interval are optimised by means of pharmacokinetic studies to determine the individual patient's FVIII or IX metabolism, the goal of maintaining a level > 1% of normal being taken as a guideline which experience has shown to yield satisfactory control of bleeding diathesis. An optimal model for prophylactic treatment needs to be applicable to haemophiliacs and acceptable to health authorities in a majority of the countries in the world. To fulfill these criteria, the Swedish model, which has been shown to yield most satisfactory outcome, can hopefully be further refined in the future. Were continuous infusion, using a recombinate concentrate with a prolonged half-life, technically feasible and socially acceptable to the child, we would probably have attained the optimal model of prophylactic treatment.},
  author       = {Lee, C A and Kessler, C M and Varon, D and Martinowitz, U and Heim, M and Ljung, R.C.R.},
  issn         = {1351-8216},
  keyword      = {Factor IX,Factor VIII,Haemophilia A,Haemophilia B,Prophylaxis,blood clotting factor,blood clotting factor 8,blood clotting factor 9,conference paper,continuous infusion,drug half life,hemarthrosis,hemophilia,human,metabolism,practice guideline,priority journal,prophylaxis,Sweden},
  language     = {eng},
  month        = {11},
  number       = {4},
  pages        = {409--412},
  publisher    = {ARRAY(0xa4ed800)},
  series       = {Haemophilia},
  title        = {Prophylactic treatment in Sweden - Overtreatment or optimal model?},
  url          = {http://dx.doi.org/10.1046/j.1365-2516.1998.440409.x},
  volume       = {4},
  year         = {1998},
}